Quels sont les risques pour la santé liés aux TAL ?
Des risques pour la santé peuvent survenir si les TAL provoquent des effets indésirables non prévus.
Risques pour la santéProtéinesBiotechnologie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Effecteurs de type activateur de transcription : Questions médicales les plus fréquentes",
"headline": "Effecteurs de type activateur de transcription : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Effecteurs de type activateur de transcription : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-20",
"dateModified": "2025-04-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Effecteurs de type activateur de transcription"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs de virulence",
"url": "https://questionsmedicales.fr/mesh/D037521",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de virulence",
"code": {
"@type": "MedicalCode",
"code": "D037521",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.946.896"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Effecteurs de type activateur de transcription",
"alternateName": "Transcription Activator-Like Effectors",
"code": {
"@type": "MedicalCode",
"code": "D000071336",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Doron Teper",
"url": "https://questionsmedicales.fr/author/Doron%20Teper",
"affiliation": {
"@type": "Organization",
"name": "Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, 700 Experiment Station Road, Lake Alfred, FL 33850, U.S.A."
}
},
{
"@type": "Person",
"name": "Nian Wang",
"url": "https://questionsmedicales.fr/author/Nian%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, 700 Experiment Station Road, Lake Alfred, FL 33850, U.S.A."
}
},
{
"@type": "Person",
"name": "Josh Tycko",
"url": "https://questionsmedicales.fr/author/Josh%20Tycko",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Stanford University, Stanford, CA 94305, USA."
}
},
{
"@type": "Person",
"name": "Michael C Bassik",
"url": "https://questionsmedicales.fr/author/Michael%20C%20Bassik",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Stanford University, Stanford, CA 94305, USA. Electronic address: bassik@stanford.edu."
}
},
{
"@type": "Person",
"name": "Lacramioara Bintu",
"url": "https://questionsmedicales.fr/author/Lacramioara%20Bintu",
"affiliation": {
"@type": "Organization",
"name": "Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. Electronic address: lbintu@stanford.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Extracapsular cataract extraction in Europe prior to Jacques Daviel.",
"datePublished": "2022-11-07",
"url": "https://questionsmedicales.fr/article/36344465",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/aos.15282"
}
},
{
"@type": "ScholarlyArticle",
"name": "Zonulopathy Identified During Cataract Extraction in Patients With Primary Angle Closure Disease.",
"datePublished": "2023-05-29",
"url": "https://questionsmedicales.fr/article/37311010",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002247"
}
},
{
"@type": "ScholarlyArticle",
"name": "Trifocal versus extended depth of focus (EDOF) intraocular lenses after cataract extraction.",
"datePublished": "2024-07-10",
"url": "https://questionsmedicales.fr/article/38984608",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD014891.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cataracts.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36565712",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/S0140-6736(22)01839-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants with presbyopia.",
"datePublished": "2023-01-27",
"url": "https://questionsmedicales.fr/article/36705482",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD012648.pub3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Toxines biologiques",
"item": "https://questionsmedicales.fr/mesh/D014118"
},
{
"@type": "ListItem",
"position": 4,
"name": "Facteurs de virulence",
"item": "https://questionsmedicales.fr/mesh/D037521"
},
{
"@type": "ListItem",
"position": 5,
"name": "Effecteurs de type activateur de transcription",
"item": "https://questionsmedicales.fr/mesh/D000071336"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Effecteurs de type activateur de transcription - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Effecteurs de type activateur de transcription",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Effecteurs de type activateur de transcription",
"description": "Comment identifier les effecteurs TAL dans un échantillon ?\nQuels tests sont utilisés pour détecter les TAL ?\nLes TAL peuvent-ils être détectés par imagerie ?\nQuels marqueurs sont associés aux TAL ?\nPeut-on utiliser des anticorps pour détecter les TAL ?",
"url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Cataract+Extraction#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Effecteurs de type activateur de transcription",
"description": "Quels sont les effets des TAL sur les cellules ?\nLes TAL provoquent-ils des symptômes cliniques ?\nComment les TAL affectent-ils les plantes ?\nLes TAL sont-ils liés à des maladies ?\nLes TAL affectent-ils le métabolisme cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Cataract+Extraction#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Effecteurs de type activateur de transcription",
"description": "Comment prévenir les effets indésirables des TAL ?\nLes TAL peuvent-ils être utilisés de manière préventive ?\nQuelles mesures de sécurité sont nécessaires lors de l'utilisation des TAL ?\nLes TAL nécessitent-ils une réglementation spécifique ?\nComment évaluer l'impact environnemental des TAL ?",
"url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Cataract+Extraction#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Effecteurs de type activateur de transcription",
"description": "Les TAL sont-ils utilisés en thérapie génique ?\nComment les TAL sont-ils appliqués en biotechnologie ?\nLes TAL peuvent-ils être utilisés pour traiter des cancers ?\nQuels sont les avantages des TAL en médecine ?\nLes TAL sont-ils sûrs pour l'utilisation humaine ?",
"url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Cataract+Extraction#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Effecteurs de type activateur de transcription",
"description": "Quelles complications peuvent survenir avec l'utilisation des TAL ?\nLes TAL peuvent-ils provoquer des réactions immunitaires ?\nComment gérer les complications liées aux TAL ?\nLes TAL peuvent-ils affecter la biodiversité ?\nQuelles sont les préoccupations éthiques liées aux TAL ?",
"url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Cataract+Extraction#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Effecteurs de type activateur de transcription",
"description": "Quels facteurs augmentent les risques liés aux TAL ?\nLes TAL sont-ils plus risqués dans certaines applications ?\nComment évaluer les risques des TAL en recherche ?\nLes TAL sont-ils associés à des risques environnementaux ?\nQuels sont les risques pour la santé liés aux TAL ?",
"url": "https://questionsmedicales.fr/mesh/D000071336?mesh_terms=Cataract+Extraction#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les effecteurs TAL dans un échantillon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par PCR, séquençage ou techniques de biologie moléculaire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les TAL ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de PCR en temps réel et des analyses de séquençage sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les TAL peuvent-ils être détectés par imagerie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les TAL sont des protéines et nécessitent des méthodes moléculaires pour leur détection."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux TAL ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs génétiques spécifiques aux TAL peuvent être utilisés pour leur identification."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des anticorps pour détecter les TAL ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anticorps spécifiques peuvent être utilisés dans des tests immunologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les effets des TAL sur les cellules ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les TAL modifient l'expression génique, influençant la croissance et la différenciation cellulaire."
}
},
{
"@type": "Question",
"name": "Les TAL provoquent-ils des symptômes cliniques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les TAL eux-mêmes ne provoquent pas de symptômes, mais leurs effets peuvent influencer la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Comment les TAL affectent-ils les plantes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent induire des réponses de défense ou des modifications de croissance chez les plantes."
}
},
{
"@type": "Question",
"name": "Les TAL sont-ils liés à des maladies ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être impliqués dans des maladies en modifiant l'expression de gènes associés."
}
},
{
"@type": "Question",
"name": "Les TAL affectent-ils le métabolisme cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en régulant des gènes clés, les TAL peuvent influencer le métabolisme cellulaire."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des TAL ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation rigoureuse des TAL avant leur utilisation est essentielle pour prévenir les effets indésirables."
}
},
{
"@type": "Question",
"name": "Les TAL peuvent-ils être utilisés de manière préventive ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être utilisés pour renforcer la résistance des plantes aux maladies, par exemple."
}
},
{
"@type": "Question",
"name": "Quelles mesures de sécurité sont nécessaires lors de l'utilisation des TAL ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des protocoles de sécurité en laboratoire et des évaluations de risque sont nécessaires."
}
},
{
"@type": "Question",
"name": "Les TAL nécessitent-ils une réglementation spécifique ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur utilisation en biotechnologie et en médecine est soumise à des réglementations strictes."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact environnemental des TAL ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études d'impact environnemental doivent être réalisées avant leur déploiement dans la nature."
}
},
{
"@type": "Question",
"name": "Les TAL sont-ils utilisés en thérapie génique ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les TAL sont utilisés pour cibler et modifier des gènes dans des thérapies géniques."
}
},
{
"@type": "Question",
"name": "Comment les TAL sont-ils appliqués en biotechnologie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont utilisés pour créer des plantes génétiquement modifiées et pour la recherche génétique."
}
},
{
"@type": "Question",
"name": "Les TAL peuvent-ils être utilisés pour traiter des cancers ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études explorent leur utilisation pour cibler des gènes spécifiques dans les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Quels sont les avantages des TAL en médecine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils permettent une modification précise de l'ADN, offrant des possibilités de traitement ciblé."
}
},
{
"@type": "Question",
"name": "Les TAL sont-ils sûrs pour l'utilisation humaine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études sont en cours pour évaluer leur sécurité et leur efficacité dans des applications cliniques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'utilisation des TAL ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets hors cible sur d'autres gènes peuvent survenir, entraînant des complications."
}
},
{
"@type": "Question",
"name": "Les TAL peuvent-ils provoquer des réactions immunitaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions immunitaires peuvent se produire si le système immunitaire reconnaît les TAL comme étrangers."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux TAL ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance étroite et des ajustements dans les protocoles d'utilisation peuvent aider."
}
},
{
"@type": "Question",
"name": "Les TAL peuvent-ils affecter la biodiversité ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur utilisation peut avoir des impacts sur la biodiversité, nécessitant une évaluation."
}
},
{
"@type": "Question",
"name": "Quelles sont les préoccupations éthiques liées aux TAL ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les préoccupations incluent les effets sur l'environnement et la modification génétique des organismes."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent les risques liés aux TAL ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation inappropriée ou non réglementée des TAL peut augmenter les risques associés."
}
},
{
"@type": "Question",
"name": "Les TAL sont-ils plus risqués dans certaines applications ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur utilisation dans des organismes vivants peut présenter des risques plus élevés."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques des TAL en recherche ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études de sécurité et des évaluations de risque doivent être menées avant l'utilisation."
}
},
{
"@type": "Question",
"name": "Les TAL sont-ils associés à des risques environnementaux ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, leur introduction dans l'environnement peut avoir des conséquences imprévues."
}
},
{
"@type": "Question",
"name": "Quels sont les risques pour la santé liés aux TAL ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des risques pour la santé peuvent survenir si les TAL provoquent des effets indésirables non prévus."
}
}
]
}
]
}
Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, 700 Experiment Station Road, Lake Alfred, FL 33850, U.S.A.
Publications dans "Effecteurs de type activateur de transcription" :
Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, 700 Experiment Station Road, Lake Alfred, FL 33850, U.S.A.
Publications dans "Effecteurs de type activateur de transcription" :
Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, 700 Experiment Station Road, Lake Alfred, FL 33850, U.S.A.
Publications dans "Effecteurs de type activateur de transcription" :
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota. Electronic address: maher@mayo.edu.
Publications dans "Effecteurs de type activateur de transcription" :
The first successful planned extracapsular cataract extraction was reported by Jacques Daviel in 1752. The history of European cataract surgery in the first half of the 18th century, immediately prece...
The proportion, clinical characteristics, and risk factors of zonulopathy in primary angle closure disease (PACD) were analyzed. Zonulopathy is an underrecognized common finding in PACD, especially in...
To examine the proportion and risk factors associated with intraoperative zonulopathy in PACD....
This is a retrospective analysis of 88 consecutive patients with PACD who underwent bilateral cataract extraction at Beijing Tongren Hospital from August 1, 2020 to August 1, 2022. Zonulopathy was dia...
Of 88 patients with PACD (67.3 ± 6.9 y old, 19 males and 69 females), the overall proportion of zonulopathy was 45.5% of patients (40/88) and 30.1% of eyes (53/176). Among the PACD subtypes, the propo...
Zonulopathy is common in PACD, especially in patients with AAC. Shallow anterior chamber depth and thick lens thickness were associated with an increased proportion of zonulopathy....
Cataract, defined as an opacity of the lens in one or both eyes, is the leading cause of blindness worldwide. Cataract may initially be treated with new spectacles, but often surgery is required, whic...
To compare visual outcomes after implantation of trifocal intraocular lenses (IOLs) to those of extended depth of focus (EDOF) IOLs. To produce a brief economic commentary summarising recent economic ...
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register), MEDLINE, Embase, and three trial registries on 15 June 2022. For our economic evaluation, we also searched MEDLINE an...
We included studies comparing trifocal and EDOF IOLs in adults undergoing cataract surgery. We did not include studies involving people receiving IOLs for correction of refractive error alone (or refr...
We used standard Cochrane methods. Two review authors working independently selected studies for inclusion and extracted data from the reports. We assessed the risk of bias in the studies, and we asse...
We included five studies that compared trifocal and EDOF lenses in people undergoing cataract surgery. Three trifocal lenses (AcrySof IQ PanOptix, ATLISA Tri 839MP, FineVision Micro F) and one EDOF le...
Distance visual acuity after cataract surgery may be similar whether the lenses implanted are trifocal IOLs or EDOF (TECNIS Symfony) IOLs. People receiving trifocal IOLs may achieve better near vision...
94 million people are blind or visually impaired globally, and cataract is the most common cause of blindness worldwide. However, most cases of blindness are avoidable. Cataract is associated with dec...
Presbyopia occurs when the lens of the eyes loses its elasticity leading to loss of accommodation. The lens may also progress to develop cataract, affecting visual acuity and contrast sensitivity. One...
To assess the effectiveness and safety of implantation with trifocal versus bifocal IOLs during cataract surgery among people with presbyopia....
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2022, Issue 3); Ovid MEDLINE; Embase.com; PubMed; ClinicalTrials...
We used standard Cochrane methodology and graded the certainty of the body of evidence according to the GRADE classification....
We identified seven studies conducted in Europe and Turkey with a total of 331 participants. All included studies assessed visual acuity using a logarithm of the minimum angle of resolution (LogMAR ch...
We found low-certainty of evidence that compared with bifocal IOL, implantation of trifocal IOL may improve uncorrected intermediate visual acuity at one year. However, there was no evidence of a diff...
Mitomycin C has been used adjunctively in various procedures, including pterygium excision. Delayed wound healing, the long-term complication of mitomycin C, can occur several years later and may rare...
A 91-year-old Thai woman had undergone pterygium excision 26 years ago, with adjunctive mitomycin C, as well as an uneventful extracapsular cataract extraction in the same year. The patient developed ...
This is a case report of a rare novel complication of mitomycin C application. Conjunctival bleb formation from the reopening of surgical wound, which was related to the previous mitomycin C use, coul...
To explore the utility of the Catquest 9SF visual function (VF) questionnaire along with visual acuity (VA) for determining appropriateness and priority for cataract surgery. To evaluate the feasibili...
Prospective multicentred interventional observational study....
Subjects undergoing sequential cataract surgery in both eyes at 4 sites in Ontario....
We recorded best-corrected VA (BCVA) and VA with current correction (CCVA) in each eye and both eyes (OU) and Catquest-9SF responses on a tablet before and after cataract surgery. Linear regression mo...
Preoperative BCVA and CCVA in the worse eye were significant predictors of change in VF (p = 0.006 and p = 0.008, respectively); subjects with worse VA had a greater improvement in VF after surgery. T...
For patient groups with equal VA, the Catquest-9SF score can help determine priority for surgery. Web-based data capture and interpretation allow for efficient virtual assessments of VF. A BCVA in the...
To evaluate the effect of Gonioscopy-assisted transluminal trabeculotomy (GATT) on macular thickness and to compare the combined GATT and cataract extraction (CE) with GATT surgery alone regarding mac...
A retrospective, comparative study was designed. The patients who underwent GATT or combined GATT and CE with preoperative and regular postoperative spectral domain optic coherence tomography analysis...
Fifty-four eyes fulfilled the inclusion criteria and were enrolled in this study, (Group 1 = 29 eyes, Group 2 = 25 eyes). The mean thicknesses of central macula (CM), superior inner macula (SIM), and ...
GATT can be a safe procedure with minimal and transient adverse effect on macular thickness and structure. Performing GATT together with CE caused no additional increase in the risk of macular thicken...
To describe the clinical and demographic characteristics of patients presenting with cataract at uveitis diagnosis treated at a single institution between 2005 and 2019 and to analyze postoperative ou...
We retrospectively reviewed the medical records of children (<18 years of age) diagnosed with cataract at their initial uveitis presentation who subsequently underwent cataract extraction. Outcome mea...
A total of 14 children (17 eyes) were included. Mean patient age was 7.2 ± 3.9 years. Methotrexate was initiated preoperatively in 11 patients; adalimumab, in 3. Primary intraocular lens was implanted...
In our study cohort, surgery for preexisting cataract at uveitis diagnosis resulted in improved visual acuity. Postoperative uveitis flare-ups were relatively uncommon, occurring in 4 of 17 eyes. Glau...
Gonioscopy-assisted transluminal trabeculotomy (GATT) and goniotomy with Kahook Dual Blade both achieved sustained reductions in intraocular pressure (IOP) and medication burden in eyes with steroid-i...
To characterize the 24-month surgical outcomes of GATT and excisional goniotomy in eyes with steroid-induced or uveitic glaucoma....
A retrospective chart review was performed of eyes with steroid-induced or uveitic glaucoma that underwent GATT or excisional goniotomy, either standalone or combined with phacoemulsification cataract...
Forty eyes of 33 patients underwent GATT, and 24 eyes of 22 patients underwent goniotomy, of which 88% and 75%, respectively, had 24-months' follow-up. Concomitant phacoemulsification cataract surgery...
Both GATT and goniotomy demonstrate favorable efficacy and safety in steroid-induced and uveitic glaucoma eyes. Both procedures achieved sustained reductions in IOP and glaucoma medication burden at 2...
